Press "Enter" to skip to content

Roche to buy gene therapy specialist Spark in $4.3 billion deal

Roche Holding AG said on Monday it will buy Spark Therapeutics in a $4.3 billion deal, as the Swiss drugmaker builds its haemophilia portfolio and seeks to keep pace in gene therapy.

Original source:

Also Read:   Avra Laboratories gets CDSCO nod to make Favipiravir API